Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus ClopidogrelJacob A. Doll, Keith A.A. Fox, Scott S. Sundseth et al.|Journal of the American College of Cardiology|2016Cited by 39
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery diseaseStefan James, David Erlinge, Suman Duvvuru et al.|Thrombosis and Haemostasis|2014Cited by 21
TCT-725 Point-of-Care Genetic Testing of Eleven CYP2C19 Single Nucleotide Polymorphisms Identifies Extensive and Reduced Metabolizers of Clopidogrel With High Accuracy in Patients With Coronary Artery DiseaseDavid Erlinge, Paul A. Gurbel, Stefan James et al.|Journal of the American College of Cardiology|2012Cited by 1
Abstract 10678: Pharmacokinetic and Pharmacodynamic Effects of Prasugrel and Clopidogrel According to CYP2C19 Genotype in Very Elderly and Non-Elderly Patients With Coronary Artery DiseasePaul A. Gurbel, David Erlinge, Brian A. Moser et al.|Circulation|2012Cited by 0